Studies from Magellan Rx Management in the Area of Biosimilars Reported (Uptake of Oncology Biosimilars: Managed Care Strategies To Improve Value-based Care Systems): Drugs and Therapies – Biosimilars

2023 APR 26 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Drugs and Therapies - Biosimilars is the subject of a report. According to news originating from Middletown, Rhode Island, by NewsRx editors, the research stated, “The use of biosimilars in oncology and as supportive agents for patients with cancer has introduced an important opportunity to expand access to cost-effective care, but their utilization remains inconsistent and is influenced by a variety of factors. Promoting the uptake of biosimilars across healthcare systems relies on improving perception and education about biosimilars, which involves multiple stakeholders, including pharmacists, providers, and patients.”

Financial support for this research came from Coherus BioSciences.

Our news journalists obtained a quote from the research from Magellan Rx Management, “Clinicians and managed care professionals must consider comparative analytical studies, clinical efficacy data, and reductions in costs of care associated with biosimilars when establishing protocols for their inclusion within formularies. Real-world switch studies in oncology biosimilars that have demonstrated bioequivalence provide basis to support efficacy and safety to transition to a biosimilar product.”

According to the news editors, the research concluded: “Incorporating oncology biosimilars into treatment pathways will be an important next step in providing value-based care to patients with cancer.”

This research has been peer-reviewed.

For more information on this research see: Uptake of Oncology Biosimilars: Managed Care Strategies To Improve Value-based Care Systems. The American Journal of Managed Care, 2022;28. The American Journal of Managed Care can be contacted at: Managed Care & Healthcare Communications Llc, 666 Plainsboro Rd, Ste 300, Plainsboro, NJ 08536, USA.

The news correspondents report that additional information may be obtained from YuQian Liu, Magellan Rx Management, Specialty Clin Solut, Middletown, RI 02842, United States.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.37765/ajmc.2022.89188. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)